ClinicalTrials.gg
RecruitingNCT06915909Updated Jul 8, 2026

Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial

An interventional study of surgery in Prostate Cancer (Adenocarcinoma), Prostate Cancer (Post Prostatectomy) and Prostate Cancer Surgery, sponsored by East and North Hertfordshire NHS Trust. Recruiting at 1 site in United Kingdom. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by East and North Hertfordshire NHS Trust · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 486 studies in Prostatic Neoplasms with a site in United Kingdom — 91 open to participants now, 158 under way, 46 of them phase 3. Prostatic Neoplasms · United Kingdom.

Planned enrollment
240th of 393
100 · median 164
Started
2025
with 24 others
No phase
80 of 486
17 open now
Primary completion
2025-12
later than 39 of 157 live
Registered
453rd of 486
by date

Among the 486 studies in Prostatic Neoplasms with a site in United Kingdom, this one is the 240th largest by planned enrollment of the 393 interventional ones that give a count, is one of 25 that started in 2025, is one of 80 with no phase, reaches primary completion later than 39 of the 157 other live ones, and was the 453rd registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

91 of the 486 studies in Prostatic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 486 studies in Prostatic Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

The 'Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial' aims to assess the feasibility of being able to review operative outcomes such as pain when comparing two commonly used surgical devices for the removal of prostate cancers. The data collected will inform methodologies for future, larger, multi-center trials investigating pain in patients undergoing prostate cancer surgery.

A robotic prostatectomy is a commonly performed surgery used to treat prostate cancer by removing the prostate gland. In order to perform the procedure, the surgeon must 'inflate' (technical term pneumoperitoneum) the patients abdomen with carbon dioxide gas using a device called an insufflator. Adequate 'inflation' of the abdomen ensures the surgeon can clearly visualise the prostate. Unfortunately, higher pressures of abdominal 'inflation' are a large contributor to intra and post-operative pain in patients having prostatectomies. The type of insufflator device used to maintain inflation pressures in the abdomen are thought to be a variable contributing to differing levels of intra and post-operative pain. Therefore, the purpose of this trial is to compare intra and post-operative pain when using two different insufflator devices when performing robotic prostatectomies. Both insufflators are already commonly used across multiple NHS Trusts.

40 patients awaiting a robotic prostatectomy at the urology department at the Lister hospital, Stevenage, will be randomised to use either the Conventional Insufflator System (CIS) {Stryker PneumoClear Insufflator} or the AIRSEAL® Insufflation System (AIS) to 'inflate' their abdomens during their prostatectomies. Data relating to various intra and post-operative outcomes will be collected in the 30 days following the patient's operation. Outcomes include levels of intra and post-operative pain, medication use, procedure time, recovery room time, length of hospital stay, post operative nausea and vomiting and adverse events. This data can be analysed to identify trends in differences in outcomes between the AIS and CIS insufflators.

An amendment has been approved to recruit an additional 60 participants, total overall recruitment is 100.

Read the detailed description

In this trial, 100 patients undergoing robotic prostatectomies will be randomised to have either the AIRSEAL® Insufflation System (AIS) or the Stryker PneumoClear Insufflator devices used to maintain pneumoperitoneum during surgery. Data relating to intra-operative and post-operative pain will be collected. This data will be used to identify any differences in outcomes between the two arms of the trial.

The main aim of this feasibility study will be to inform the feasibility and design of a subsequent definitive full-scale trial. The feasibility trial will collect data about recruitment, study conduct, and assessment methods. The objectives of the feasibility are to

  • Assess recruitment rates
  • Evaluate whether the study can run in line with the study protocol
  • Identify the feasibility of collecting clinical data
  • Evaluate treatment-based adverse events, serious adverse events, anticipated adverse device effects, unanticipated adverse device effects and all device deficiencies and use errors, regardless of relationship to an adverse event
  • Estimate the likely magnitude of the effect of the intervention. To allow for estimation of the sample size for the full trial

The subsequent large scale, multi-center trial following this feasibility trial will focus on severity of pain during and immediately after surgery in the recovery room and then by 6-hour increments, measured by a 0 - 10 Numeric Rating Scale (NRS) and a PMD-200 nociception non-invasive monitor as the primary outcome

Secondary outcomes include:

Pre-Operative

  1. Pre-op vitals including height and weight
  2. Pre-op labs

Intra-operative

  1. Insufflation Pressure
  2. Estimated blood loss
  3. Blood transfusion (intra-operative)
  4. Procedure time (initial incision to closure)
  5. Surgeon-determined need to increase IAP beyond "study pressure"
  6. Administration of transversus abdominis plane block
  7. Urine output
  8. Anesthetic/pain medication administration
  9. MedaSense PMD-200 monitor for pain documentation
  10. Intraoperative Peak Airway Pressure every 15 minutes
  11. Intraoperative End Tidal Carbon Dioxide (ETCO2) every 15 minutes

Post-Operative During hospital discharge, all subjects will be evaluated for incidence and severity of pain using a 0-10 numeric rating scale (NRS) and records of medication use and a PMD-200 monitor. These data will be captured in the Case Report Forms.

Recovery room:

  1. Time in recovery room
  2. Post-op pain incidence and severity (abdominal) NRS
  3. Pain medications
  4. Post- op labs (CBC, Chem-7) per standard of care
  5. Vital signs 24 hr

Discharge:

  1. Post-op pain incidence and severity (abdominal) NRS
  2. Presence or absence of postoperative nausea or vomiting
  3. Pain medications
  4. Length of hospital stay
  5. Pain Interference and Pain Intensity short form surveys
  6. Any complications that were observed. Post-operative complications through 30 days, reported using Clavien-Dindo Classification, including 30-day mortality
  7. Return to operating room within 24 hour
  8. Readmission to hospital within 30 days

Classification, including 30-day mortality

All Adverse Events (intra-operative and post-operative through 30 days):

  1. Adverse Events
  2. Serious Adverse Events
  3. Anticipated Adverse Device Effects
  4. Unanticipated Adverse Device Effects 5 All device deficiencies and use errors, regardless of relationship to an adverse event

Patients under the care of the urology department at the Lister Hospital, Stevenage will be listed in clinic for a robotic prostatectomy. If patients meet the eligibility criteria for the trial, they will be approached and informed of the RALP clinical trial during their clinic consultation, by a member of the clinical team (likely a urological consultant).

Patients will be provided with a patient information sheet informing them of the aims and methodology of the trial. Members of the research department will be able to answer any outstanding questions patients might have.

Written informed consent will be obtained from eligible patients (n=40) willing to participate in the trial. If patients consent, their GP will subsequently be written to and informed of their involvement in the trial.

Pre-Operative data collection:

Within 30 days of a subject's scheduled procedure, members of the research department at Lister hospital will obtain a medical history and record the subject's demographic (age, race, sex and date of birth) and baseline information (height, weight, and systolic/diastolic blood pressure). Within 30 days prior to the planned procedure date, obtain serum blood tests per standard of care. These will typically include:

  • FBC • Renal function test • CRP This data, along with all subsequent trial related data will be anonymised and subsequently inputted into a database created by the Centre for Health Services and Clinical Research at the University of Hertfordshire.

Preoperative Randomization:

Randomization will be done electronically via a database which is facilitated by the University of Hertfordshire. Patients will be randomized 1:1 to either AIS (at 8 mmHg) or Stryker PneumoClear Insufflator Arm 1: AIRSEAL® Insufflation System (AIS) - 8 mmHg Arm 2: Stryker PneumoClear Insufflator - 8 mmHg.

Methods and Procedure:

Patients will undergo their robotic assisted prostatectomy with the use of either the AIRSEAL® Insufflation System (AIS) or Stryker PneumoClear Insufflator depending on which arm of the trial they have been randomized to. Patients will be blinded to the intervention (AIRSEAL® Insufflation System (AIS) or Stryker PneumoClear Insufflator). Both systems are commonly used devices across many NHS trusts and there is currently no evidence comparing patient outcomes between use of the two devices.

This study will be conducted at one site by one surgeon performing 40 total procedures. Study subjects will be prepared for surgery per standard institutional policy and practice. Standard operative procedures will be followed.

Case Report Forms will be also be used to collect data relating to pre-operative, intra-operative and post-operative outcomes. This data will relate to outcomes such as intra-operative pain, post operative pain scores, medication use, duration of hospital stay, presence of nausea or vomiting etc...

The final patient follow up will be in a clinic appointment 30 days following their operation. Ongoing post-operative outcomes will be assessed (pain scores, medication use, adverse events etc...).

Data will be inputted on the database which is subsequently processed and statistically analysed and reviewed. Differences in outcomes between the two arms of the trial may be identified.

Once the aforementioned data has been processed and reviewed, results may be published and also distributed to those trial participants who wished to receive ongoing information and results from the trial.

The outcomes of this research will be used to inform future research such as a full scale trial with a larger number of patients and larger volume of data

03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)
  • Prostate Cancer (Post Prostatectomy)
  • Prostate Cancer Surgery
  • Prostate Cancers
  • Prostate Neoplasm
  • Prostatectomy

Keywords

  • prostate cancer
  • prostatectomy
  • robotic prostatectomy
  • post-operative pain
  • pain
  • Stryker PneumoClear insufflator
  • AirSeal Insufflation System
  • intra-operative pain
  • Medasense
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient indicated for non-emergent robotic Prostatectomy surgery
  • Patients (or appropriate legal representatives) able to provide written to participate in the study
  • Males, aged 18 to 75 years
  • Have no significant psychopathology that could limit the subject's ability to understand the procedure, comply with medical, surgical, and/or behavioural recommendations and office visits
  • Are American Society of Anaesthesiologists (ASA) Class I, II, or III);

Exclusion criteria

Exclusion Criteria:

  • Patient participation in a different clinical study within 90 days before screening and for the duration of this trial (unless previously approved by the investigator and Sponsor);
  • Patients requiring any surgical procedure in addition to Prostatectomy and or / Pelvic Lymph node dissection
  • Previous pelvic surgery or previous malabsobtion or restrictive procedures performed for the treatment of obesity
  • Inability to provide
  • Unable or unwilling to attend follow-up visits and examinations
  • Uncontrolled hypertension (=/>Systolic: 180 mmHg/Diastolic: 120 mmHg) and/or diabetes mellitus (Blood sugar level: >200 mg/dL)
  • Patients who fall into (ASA) Class ≥ IV
  • History of chronic alcohol or drug abuse within 2 years of the screening visit
  • Chronic renal failure or on dialysis
  • Significant complicating medical history or
  • History or presence of pre-existing connective tissue disease, e.g., systemic lupus erythematosus or scleroderma
  • Immunocompromised such as that resulting from chronic oral use, chemotherapeutic agents, or immune deficiency disorders;
  • Any medical condition which precludes compliance with the study
  • Subjects with any other unstable medical disorder, life threatening disease, or conditions that, in the opinion of the investigator, may jeopardize the subject's well-being and/or the soundness of this clinical study or which would contra-indicate a surgical procedure.
  • Previous or current history of being on regular analgesia / pain killers
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Stryker PneumoClear insufflator

    Measuring patient's pain during and after a robotic prostatectomy using the Stryker PneumoClear insufflator. 20 patients will be randomised and assigned to this arm of the trial. Post-op pain outcomes will be compared to the control arm (standard of care), the AirSeal Insufflation System.

    Device: surgery

  • No intervention
    AirSeal® Insufflation System

    Measuring patient's pain during and after a robotic prostatectomy using the AirSeal® Insufflation System. 20 patients will be randomised and assigned to this arm of the trial. This device is the standard of care at the Lister hospital, Stevenage, UK.

Interventions

  • Devicesurgery

    100 patients randomised to two arms will undergo robotic prostatectomies using either the control AirSeal® Insufflation System (AIS) or the intervention Stryker PneumoClear Insufflator. Intra-operative and post-operative pain will be compared between the two arms of the trial.

    Also known as: Robotic assisted laparoscopic prostatectomy

06

What researchers measure

Primary outcomes

  1. Recruitment rates

    Time frame: Through study completion estimated to be 6-12 months

  2. Evaluate treatment-based adverse events, serious adverse events, anticipated adverse device effects, unanticipated adverse device effects and all device deficiencies and use errors, regardless of relationship to an adverse event.

    Time frame: Through study completion estimated to be 6-12 months

  3. Pre-op vitals

    Bloods pressure, heart rate, oxygen saturations, respiration rate, temperature

    Time frame: Baseline/day 1

  4. Pre-op BMI (height and weight)

    kg/m\^2

    Time frame: Baseline/day 1

  5. Pre-op labs

    Pre-op FBC, U\&E, CRP and PSA bloods

    Time frame: Baseline/day 1

  6. Insufflation Pressure

    Intraoperative insufflation pressure (mmHg)

    Time frame: Perioperative

  7. Estimated blood loss

    Estimated intra-operative blood loss (ml)

    Time frame: Perioperative

  8. Blood transfusion

    Intra-operative blood transfusions (number of units of blood e.g 0, 1, 2, 3 etc...)

    Time frame: Perioperative

  9. Procedure time (initial incision to closure)

    Number of minutes from incision to closure

    Time frame: Perioperative

  10. Surgeon-determined need to increase IAP beyond "study pressure"

    Need to increase insufflation pressure intra-operatively (mmHg)

    Time frame: Perioperative

  11. Administration of transversus abdominis plane block

    Was a transversus abdominis plane block administered (yes or no)

    Time frame: Perioperative

  12. Anesthetic/pain medication administration

    Intra-operative administration of analgesia (morphine milligram equivalent units)

    Time frame: Perioperative

  13. MedaSense PMD-200 monitor for pain documentation

    Intra-operative pain score (NOL score 0-100)

    Time frame: Perioperative

  14. Intraoperative Peak Airway Pressure every 15 minutes

    Intra-operative PAP (cmH2O)

    Time frame: Perioperative

  15. Intraoperative End Tidal Carbon Dioxide (ETCO2) every 15 minutes

    Intra-operative ETCO2 (mmHg)

    Time frame: Perioperative

  16. Time in recovery room

    Number of minutes spent in post-op recovery

    Time frame: Perioperative

  17. Post-op pain incidence and severity

    Pain measured using visual analogue scale, numerical rating scale and pain incidence and interference surveys. Pain surveys done at 1, 3, 6, 12, 18, 24 hours and day 7 and day 30 post-operation.

    Time frame: Day 1-30 post-op/post-intervention

  18. Post-op analgesia usage

    Post-op analgesia usage on discharge (morphine milligram equivalent units)

    Time frame: Day 1-30 post-op/post-intervention

  19. Post- op labs as per standard of care

    FBC, U\&E, CRP

    Time frame: Day 1-30 post-op/post-intervention

  20. Vital signs 24 hr

    Blood pressure, heart rate, respiration rate, oxygen saturations, temperature

    Time frame: Day 1 post-op/post-intervention

  21. Presence or absence of postoperative nausea or vomiting

    Presence of nausea/vomiting in the post-op period

    Time frame: Day 1 post-op/post-intervention

  22. Length of hospital stay

    Duration of hospital admission (hours)

    Time frame: Day 1-30 post-op/post-intervention

  23. Any complications that were observed. Post-operative complications through 30 days, reported using Clavien-Dindo Classification, including 30-day mortality

    Reporting of post-operative complications

    Time frame: Day 1-30 post-op/post-intervention

  24. Return to operating room within 24 hour

    Reason for return to the operating room and number of returns to operating room

    Time frame: Day 1-30 post-op/post-intervention

  25. Readmission to hospital within 30 days

    Reason and number of readmissions to hospital

    Time frame: Day 1-30 post-op/post-intervention

  26. All Adverse Events (intra-operative and post-operative through 30 days)

    Documented using the "Common Terminology Criteria for Adverse Events" (CTCAE) v5.0

    Time frame: Day 1-30 post-op/post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Dec 2025, 7 months.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 7 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Apr 8, 2025
StartActual
Apr 22, 2025
Primary completionActual
Dec 17, 2025
CompletionEst.
Aug 17, 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06915909
Lead sponsor
East and North Hertfordshire NHS Trust
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Apr 22, 2025
Primary completion
Dec 17, 2025
Completion
Aug 17, 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Nikhil Vasdev
Contact
nikhil.vasdev@nhs.net
+441438284042

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion